Nutriband Inc. entered into an exclusive distribution agreement with Costa Rica‑based Innomedica for its AVERSA Fentanyl patch, contingent on FDA approval, and for all sports tape products manufactured by its Pocono Pharmaceuticals subsidiary. Innomedica will handle distribution throughout Costa Rica and will finance the regulatory approvals required for the AVERSA Fentanyl launch in that market.
The agreement expands Nutriband’s presence into Central America and provides a dedicated channel for its first‑in‑class abuse‑deterrent fentanyl patch. By securing a local partner that will also fund the regulatory pathway, Nutriband positions itself to accelerate market entry once FDA clearance is obtained, while simultaneously broadening the reach of its sports tape line.
Nutriband’s AVERSA Fentanyl program has been progressing along a 505(b)(2) NDA pathway. The company targeted an NDA filing in Q1 2025, held a Type C meeting with the FDA on September 18 2025 to discuss chemistry, manufacturing, and controls, and is preparing for an IND filing to support a human abuse‑potential study. The distribution deal therefore aligns with the company’s regulatory timeline and could shorten the time to market in Costa Rica.
Financial terms of the agreement were not disclosed. Innomedica will finance the regulatory approvals for AVERSA Fentanyl, but no revenue‑sharing or upfront payment details were provided. The sports tape segment has shown strong growth, with a 219% year‑over‑year increase in Q1 2024 and $667,000 in revenue in Q1 2025, up 63% from the prior year, underscoring the potential upside of the expanded distribution network.
Analysts have set a target price of $15 for Nutriband, reflecting confidence in the company’s growth prospects and the strategic value of the new distribution partnership.
The deal underscores Nutriband’s strategy to diversify its revenue streams and leverage its innovative AVERSA technology in new markets while capitalizing on the momentum of its sports tape business.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.